OrthoTrophix Homepage

Latest News

December 14, 2023
OrthoTrophix Licensed TPX-100 to American Regent for the United States

June 1, 2022
TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022

April 8, 2022
TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis


OrthoTrophix is a biopharmaceutical company focused on development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone and cartilage. The primary focus of OrthoTrophix is development of a first-in-class disease modifying osteoarthritis drug (DMOAD). The company’s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other beneficial clinical parameters in knee osteoarthritis (OA) patients. The clinical benefits are associated and correlated with reduction in pathological changes of bone and cartilage structures in the OA knee.